A pilot transcriptomic study of a novel multitargeted BRT regimen for anti–MDA5 antibody-positive dermatomyositis: improving survival over conventional therapy

BackgroundAnti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5-DM) is associated with severe outcomes, primarily due to rapidly progressive interstitial lung disease (RP-ILD), which is often refractory to standard therapies such as calcineurin inhibitors (e.g., tac...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Moe Tokunaga, Yu Nakai, Yoshiharu Sato, Mitori Hiratsuka, Yoshinori Matsumoto, Takeshi Nakatsue, Takako Saeki, Takatsune Umayahara, Jun Wada, Yoshinobu Koyama
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2025-08-01
سلاسل:	Frontiers in Immunology
الموضوعات:	anti-MDA5 antibody-positive dermatomyositis (MDA5-DM) JAK inhibitor baricitinib rituximab multitargeted treatment IFN signature
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1568338/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!